ADC Therapeutics(ADCT) - 2024 Q3 - Quarterly Results

Exhibit 99.1 ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66 annual American Society of Hematology Annual Meeting in December 2024 th Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a. ...